Beam Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Beam Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BEAM
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201.
CEOJohn Evans
CEOJohn Evans
Employees483
Employees483
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2017
Founded2017
Employees483
Employees483
BEAM Key Statistics
Market cap3.25B
Market cap3.25B
Price-Earnings ratio-7.98
Price-Earnings ratio-7.98
Dividend yield—
Dividend yield—
Average volume2.25M
Average volume2.25M
High today$35.51
High today$35.51
Low today$31.91
Low today$31.91
Open price$35.33
Open price$35.33
Volume2.08M
Volume2.08M
52 Week high$36.44
52 Week high$36.44
52 Week low$13.53
52 Week low$13.53
Stock Snapshot
With a market cap of 3.25B, Beam Therapeutics(BEAM) trades at $32.45. The stock has a price-to-earnings ratio of -7.98.
During the trading session on 2026-01-15, Beam Therapeutics(BEAM) shares reached a daily high of $35.51 and a low of $31.91. At a current price of $32.45, the stock is +1.7% higher than the low and still -8.6% under the high.
Trading activity shows a volume of 2.08M, compared to an average daily volume of 2.25M.
The stock's 52-week range extends from a low of $13.53 to a high of $36.44.
The stock's 52-week range extends from a low of $13.53 to a high of $36.44.
Analyst ratings
83%
of 18 ratingsBuy
83.3%
Hold
16.7%
Sell
0%
People also own
Based on the portfolios of people who own BEAM. This list is generated using Robinhood data, and it’s not a recommendation.